Business Context and Reporting Period
This Form 8-K filing by Apyx Medical Corp (APYX) covers the date of June 11, 2026. The report details the entry into a material definitive agreement regarding a change in corporate leadership structure.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a governance and compensation agreement.
Material Changes
- Leadership Appointment: Stavros Vizirgianakis, previously the Chairman of the Board, has been appointed as Executive Chairman of the Board.
- Role Definition: Mr. Vizirgianakis will provide strategic leadership, governance oversight, and support investor engagement. He will not serve as an officer or employee and is not designated as an "executive officer" under Rule 3b-7.
- Compensation Grant: The Board approved a grant of 450,000 restricted stock units (RSUs) under the 2023 Share Incentive Plan.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard incorporation of the Letter Agreement by reference. The vesting schedule for the RSUs is as follows:
- 150,000 RSUs vest immediately on June 11, 2026.
- 150,000 RSUs vest ratably over 12 months beginning on the first anniversary of the grant date.
- 150,000 RSUs vest ratably over 12 months beginning on the second anniversary of the grant date.
Investor Verification Checklist
- Verify the full terms of the Letter Agreement filed as Exhibit 10.1.
- Confirm the impact of the new Executive Chairman role on the company's strategic direction.
- Review the 2023 Share Incentive Plan to understand the full conditions attached to the RSU grant.
- Monitor future filings for any changes in the company's executive officer roster or financial performance resulting from this leadership shift.